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Plasma Symmetric Dimethylarginine Concentration in Dogs with
Acute Kidney Injury and Chronic Kidney Disease
D.P. Dahlem , R. Neiger, A. Schweighauser, T. Francey, M. Yerramilli, E. Obare, and
S.M.L. Steinbach
Background: Symmetric dimethylarginine (SDMA) is considered a biomarker for early detection of renal dysfunction in
human patients with acute kidney injury (AKI). At present, no studies exist analyzing the relevance of SDMA in dogs with
AKI.
Hypothesis/objectives: SDMA would correctly identify dogs with renal disease but would not be able to diﬀerentiate
between AKI and CKD.
Animals: Eighteen healthy control dogs, 48 dogs with AKI, and 29 dogs with CKD.
Methods: Prospective study. Dogs with kidney disease were categorized as having AKI or CKD according to the history,
clinical signs, laboratory ﬁndings, and results of diagnostic imaging. Plasma SDMA concentration was measured by IDEXX
Laboratories. SDMA/creatinine ratio was calculated in dogs with AKI or CKD.
Results: Median SDMA concentrations were 8.5 lg/dL (6–12 lg/dL), 39.5 lg/dL (8–>100 lg/dL), and 35 lg/dL (12–
>100 lg/dL), in healthy, AKI, and CKD, respectively. SDMA concentrations were signiﬁcantly higher in dogs with AKI
(P < .0001) or CKD (P < .0001) in comparison with healthy dogs. Median SDMA/creatinine ratio in dogs with AKI and
CKD was 6.5 (1.7–20.9) and 10 (2.4–33.9) (P = .0004), respectively. Although there was overlap of the SDMA/creatinine
ratio in dogs with AKI or CKD, it was signiﬁcantly higher in dogs with CKD compared to dogs with AKI (P = .0004).
Conclusions and Clinical Importance: In this population, SDMA was suitable for identifying dogs aﬀected by AKI or
CKD, but could not diﬀerentiate between them.
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Despite the availability of intensive care treatments,AKI has a high fatality rate.1–4 Early recognition
and intervention is a necessity to eﬀectively treat dogs with
AKI, as in contrast to CKD, AKI is reversible.5 Therefore
markers for early detection of kidney injury are needed.
At present, renal disease is mainly diagnosed based
on an elevation of serum creatinine concentration.
Creatinine concentration can be aﬀected by age, sex,
muscle mass, and hydration status. A loss of about
75% of renal function is considered necessary for serum
creatinine concentration to rise above the upper refer-
ence interval.6 Creatinine is usually considered an insen-
sitive marker to reliably diagnose AKI, although
sensitivity might be improved by applying the most
recent AKI grading criteria from the International
Renal Interest Society (IRIS).a
The use of special biomarkers to recognize ongoing
kidney injury facilitates the diﬀerentiation of AKI from
CKD in human medicine and allows an early detection
of kidney damage.7 Because of their simple determina-
tion, these markers even seem to be superior to the gold
standard of clearance methods for determining glomeru-
lar ﬁltration rate (GFR).8–10
Symmetric dimethylarginine (SDMA) is a relatively
newly discovered renal biomarker. SDMA is primarily
eliminated by renal excretion. Therefore, it is an
endogenous marker of GFR. It is not inﬂuenced by
muscle mass, which is an advantage in comparison with
creatinine.11 So far, SDMA has been used successfully
to diagnose CKD in dogs and cats.12–16
SDMA is an important biomarker for early detection
of renal dysfunction in human nephrology studies about
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patients with AKI.17–19 However, we are not aware of
data on SDMA for dogs with AKI.
The aims of this study were to report SDMA concen-
tration in dogs with AKI and to investigate whether
SDMA might be a suitable biomarker to diﬀerentiate
AKI from CKD. Secondly, we aimed to assess whether
SDMA might have prognostic value in dogs with AKI.
Material and Methods
Study Design
Eighteen healthy dogs were included as a control group. The
dogs were owned by staﬀ members of the small animal clinic of
the Justus-Liebig University Giessen (JLU). They were considered
healthy based on physical examination, complete blood cell count,
plasma biochemistry proﬁle, and urinalysis with urine culture.
GFR was measured by plasma sinistrin clearance as described
previously.20 The study was approved by the state ethics and
welfare committee Hessia (number 35/2011).
Blood samples collected for a previous study to investigate renal
biomarkers in dogs with AKI or CKD were analyzed for SDMA.
Dogs with AKI and CKD were prospectively included and classi-
ﬁed as previously published.10 Brieﬂy, dogs presented between
November 2010 and November 2011 with current or historical
renal azotemia were eligible for the study. Dogs also were included
if they developed renal azotemia during hospitalization. Two uni-
versity clinics were involved: the internal medicine service of the
JLU and the Small Animal Clinic of the Vetsuisse Faculty of
the University of Bern (VFUB). Inclusion criteria were similar to
the previous study.10 Brieﬂy, renal azotemia was deﬁned as a
plasma creatinine concentration ≥1.4 mg/dL (upper laboratory ref-
erence value) and plasma urea concentration ≥54 mg/dL (upper
laboratory reference value) persisting at least 24 hours after cor-
rection of prerenal factors21 together with a urine speciﬁc gravity
(USG) <1.025. If no initial urine was available, response to ﬂuid
therapy was used to determine whether a dog had prerenal azote-
mia. If azotemia resolved within 24 hours of ﬂuid therapy, the dog
was considered to have prerenal azotemia and was subsequently
excluded. Dogs with known or suspected acute-on-chronic kidney
disease were excluded. Dogs with known CKD in IRIS stage 1
were included. As no urinary biomarkers were assessed, dogs with
suspected or proven urinary tract infection were included.
In each dog, one heparin plasma sample was obtained in the
ﬁrst 24 hours after presentation or after development of azotemia.
The plasma samples were frozen within 6 hours, stored at 80°C
for a maximum of 5 years, and batched for analysis.
Based on history, clinical course, laboratory, and ultrasono-
graphic ﬁndings, dogs were assigned either to have AKI or CKD.
Criteria used to assign a dog to the AKI group were acute onset
of clinical signs and azotemia in a previously healthy dog, signs of
acute tubular injury on urinalysis (e.g, glucosuria, urinary casts),
imaging ﬁndings compatible with AKI such as perirenal free ﬂuid
or enlarged kidneys, as well as the absence of chronic changes or
resolution or marked improvement of azotemia within 30 days of
discharge. IRIS AKI grading criteria were used for further classiﬁ-
cation into AKI grade I–V on the day of inclusion.a On the basis
of the cause for AKI, dogs in this group were further subdivided
into dogs having leptospirosis or other disease. All dogs with lep-
tospirosis were presented to the VFUB. Dogs were diagnosed with
leptospirosis based on a positive PCR on urine, a 4-fold titer
increase in paired microagglutination tests (MAT), a single MAT
titer ≥1:800 for nonvaccinal serovars or a single MAT titer
≥1:3200 for vaccinal serovars.10,21,22 Dogs that were suspected to
have leptospirosis based on laboratory results and clinical course
but died before diagnosis could be proven were considered not to
have leptospirosis (n = 4).10 Criteria used to assign a dog to the
CKD group were previous history of CKD in the absence of acute
deterioration, laboratory ﬁndings compatible with CKD (e.g, non-
regenerative anemia), imaging ﬁndings compatible with CKD, such
as cystic lesions or irregular kidneys, or stable azotemia within
30 days after discharge.1,23
Dogs with acute-on-chronic kidney disease, prerenal, and
postrenal azotemia were excluded.
SDMA Assay
Plasma SDMA concentration was measured by liquid chro-
matography-mass spectrometry.16 The sample analysis for SDMA
was performed by API4000 coupled with Shimadzu Nexera as pre-
viously described.13,b In dogs with SDMA concentration above the
upper detection limit of 100 lg/dL, a value of 101 lg/dL was
assigned for statistical analysis.
SDMA/Creatinine Ratio
In dogs with kidney disease, a SDMA/creatinine ratio (lg/mg)
was calculated by dividing the SDMA concentration (lg/dL) by
the creatinine concentration (mg/dL).c In dogs with SDMA con-
centrations above the upper detection limit of the assay (100 lg/
dL), the ratio was not calculated. A SDMA/creatinine ratio >10
has a poor prognosis in dogs and cats with CKD.c This cutoﬀ was
therefore used to analyze survival data in dogs with CKD or AKI.
Statistics
Statistical analysis was performed by statistical software Prism
6.d Results of statistical analysis are shown as median and range
or median and 25th-75th percentile. Distribution was tested by
D’Agostino and Pearson omnibus normality test. As some data
were not normally distributed, nonparametric tests were used for
statistical analysis. Spearman’s correlation was calculated between
SDMA and creatinine concentration in all groups (healthy, AKI,
CKD). Mann-Whitney test was used to compare creatinine con-
centration in dogs with AKI or CKD as well as SDMA and
SDMA/creatinine ratio in dogs with kidney disease alive or
deceased 30 days after discharge. Fisher’s Exact test was used to
compare survival data (yes/no) in dogs with AKI or CKD with
SDMA/creatinine ratio >10 or ≤10. SDMA concentration and
SDMA/creatinine ratio between the diﬀerent groups were com-
pared by the Kruskal-Wallis test. Post hoc assessment to calculate
signiﬁcant diﬀerences among the groups was performed by the
Dunn’s Test with correction of alpha for multiple comparisons.
Statistical signiﬁcance was set at P < .05.
Results
Plasma SDMA concentration was measured in a total
of 95 dogs. Included were 18 healthy dogs, 48 dogs with
AKI and 29 dogs with CKD.
There were 49 male (34 neutered) and 46 female dogs
(22 spayed). The median age was 5.3 years (range
1–16 years). A variety of breeds were included.
Healthy dogs
The clinicopathologic data at inclusion are listed in
Table 1. SDMA concentration was signiﬁcantly lower
in the healthy dogs (8.5 lg/dL; range 6.0–12.0 lg/dL) in
comparison with the dogs with AKI (39.5 lg/dL; 8.0–
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>100 lg/dL; P < .0001) or CKD (35.0 lg/dL; 12.0–
>100 lg/dL; P = .0077) (Fig 1). Glomerular ﬁltration rate
was 3.6 mL/kg/min (2.2–5.5 mL/kg/min) and was signiﬁ-
cantly correlated with both the creatinine (r = 0.61,
P = .0072) and the SDMA concentration (r = 0.49,
P = .041). Creatinine and SDMA concentration also were
signiﬁcantly correlated (r = 0.55, P = .017; Fig 2).
Dogs with Kidney Disease
Clinicopathologic data at inclusion of dogs with AKI
or CKD are shown in Table 1. SDMA concentration in
dogs with AKI or CKD was not signiﬁcantly diﬀerent
between the two groups (Fig 1). Creatinine concentra-
tion was higher in dogs with AKI (6.6 mg/dL; 1.8–
21.0 mg/dL) compared to dogs with CKD (3.6 mg/dL;
1.0–13.2 mg/dL) (P = .0002). As in healthy dogs, crea-
tinine and SDMA concentration showed a signiﬁcant
correlation (AKI: r = 0.40, P = .0051, CKD: r = 0.74,
P < .0001; Fig 2). Correlation over all groups was mod-
erate, but signiﬁcant (r = 0.74, P = <.0001).
Using the AKI grading criteria, AKI grade II was
detected in 3 dogs (6%), AKI grade III in 15 dogs
(31%), AKI grade IV in 17 dogs (35%), and AKI grade
V in 13 dogs (28%). Median SDMA concentration in
dogs with AKI grade II, III, IV, and V was 34 lg/dL
(21–46 lg/dL), 30 lg/dL (8–54 lg/dL), 45 lg/dL (15–
77 lg/dL), and 49 lg/dL (22–>100 lg/dL), respectively.
As only three dogs were classiﬁed as AKI grade II,
AKI grade II and III were combined for statistical anal-
ysis (AKI grade II + III). AKI grade II + III had signif-
icantly lower SDMA concentration than AKI grade IV
(P = .0218), but not signiﬁcantly lower than AKI grade
V (P = .1176). SDMA concentrations in AKI grade IV
and V were similar (P = >.99).
Among dogs with AKI, leptospirosis was identiﬁed in
23 of 48 dogs (48%). SDMA concentration was similar
(P > .99) in dogs with AKI caused by leptospirosis
(34 lg/dL; 8.0–>100 lg/dL) compared to dogs with
AKI from other causes (41 lg/dL; 15.0–>100 lg/dL).
The SDMA/creatinine ratio could be calculated in
46/48 dogs with AKI and 27/29 dogs with CKD. It was
signiﬁcantly (P = .0004) lower in dogs with AKI
(6.4 lg/mg; 1.7–20.9 lg/mg) compared to dogs with
CKD (10 lg/mg; 2.4–33.9 lg/mg), but showed signiﬁ-
cant overlap between the groups (Fig 3). SDMA/crea-
tinine ratio was similar (P = .0576) in dogs with mild
CKD (n = 9, IRIS CKD stage 1 & 2: 12 lg/mg; 8.5–
33.9 lg/mg) compared to dogs with more progressed
azotemia (n = 18, IRIS CKD stage 3 & 4: 9.6 lg/mg;
2.4–15.3 lg/mg).
Table 1. Clinical and clinicopathologic data in healthy dogs and dogs with acute kidney injury (AKI) and dogs
with chronic kidney disease (CKD)
Variable
[reference range]
Healthy
Median (range)
AKI
Median (range)
CKD
Median (range)
Age (years) 3.5 (1.0–11.0)
n = 18
7.0 (1.0–12.0)a
n = 48
6.0 (1.0–15.0)a
n = 29
Body Weight (kg) 27.5 (8.1–58)
n = 18
23.5 (1.9–64.0)
n = 47
18.6 (2.4–43.0)
n = 29
Urea (mg/dL)
[19.8–58.9]
40.7 (25.0–75.6)
n = 18
143.0 (31.4–306.9)a,b
n = 48
244.5 (54.1–701.9)a
n = 29
Creatinine (mg/dL)
[0.6–1.4]
0.9 (0.6–1.2)
n = 18
6.6 (1.8–21.0)a,b
n = 48
3.6 (1.0–13.2)a
n = 29
Potassium (mEq/L)
[3.4–4.4]
4.0 (3.7–4.7)
n = 18
4.6 (2.9–7.9)a
n = 48
4.3 (3.2–7.0)
n = 29
Phosphorus (mg/dL)
[2.5–6.5]
4.2 (2.6–5.4)
n = 18
11.9 (1.8–30.3)a,b
n = 48
5.2 (1.9–27.4)a
n = 29
USG 1.038 (1.021–1.050)
n = 18
1.016 (1.008–1.035)a
n = 26
1.014 (1.006–1.024)a
n = 26
USG, urine speciﬁc gravity.
aP < .05 versus healthy.
bP < .05 versus CKD.
Fig 1. Symmetric dimethylarginine (SDMA) concentration in
healthy dogs, dogs with acute kidney injury (AKI), and dogs with
chronic kidney disease (CKD). Lines represent median and 25th–
75th percentile.
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Survival data (alive or dead 30 days post discharge)
was available for all dogs. SDMA and SDMA/crea-
tinine ratio were similar between survivors and nonsur-
vivors in all dogs with kidney disease (P = .11; P = .40)
and in dogs with AKI (P = .24, and P = .29, respec-
tively) and CKD (P = .33, and P = .44, respectively).
Dogs with AKI or CKD with a SDMA/creatinine ratio
>10 were not more likely to die within 30 days of dis-
charge than dogs with a SDMA/creatinine ratio ≤10
(P = .46; AKI: P = .16; CKD P = 1).
Discussion
Creatinine and SDMA concentrations were signiﬁ-
cantly higher in dogs with renal azotemia compared to
healthy dogs. Both creatinine and SDMA are markers
of GFR, and creatinine, as well as SDMA, correlates
inversely with GFR.e SDMA concentration in dogs
with CKD signiﬁcantly correlates with creatinine
concentration.e This was conﬁrmed in the current study.
Based on previous study results, SDMA allows earlier
detection of chronic kidney disease in dogs than
creatinine.24,f Our study design did not allow evaluation
of SDMA as a marker of early kidney disease in AKI.
No signiﬁcant diﬀerence was seen in the plasma con-
centration of SDMA between dogs with AKI and dogs
with CKD. This was expected, as SDMA is mainly a
marker of ﬁltration.13,16,e Reduction of GFR is seen in
both AKI and CKD. A direct comparison of SDMA
with GFR in these groups would have been valuable,
but GFR was measured only in the group of healthy
dogs in our study.
Creatinine concentration was signiﬁcantly higher in
dogs with AKI compared to CKD (Table 1), although
SDMA concentration was similar between groups.
Despite the signiﬁcant correlation of SDMA and crea-
tinine in the examined population of dogs, this correla-
tion was much lower in the dogs with AKI compared
to the dogs with CKD. This was unexpected because of
the potential lower muscle mass in dogs with advanced
CKD and the inﬂuence of muscle mass on creatinine
concentration.6 A lower correlation of SDMA and crea-
tinine in the dogs with CKD would be expected. The
reason of this discrepant correlation result in our study
was unclear. Also, SDMA/creatinine ratio was signiﬁ-
cantly higher in dogs with CKD in comparison with
dogs with AKI (Fig 3). Other than by GFR, creatinine
concentration is mainly inﬂuenced by muscle mass,
which is reduced in many dogs with CKD.6,25 Dogs
with AKI are expected to have a normal body condi-
tion at presentation.1 As CKD might lead to more pro-
found muscle wasting compared to AKI, a higher
SDMA/creatinine ratio in dogs with progressed CKD
might be a result of decreased muscle mass. SDMA/cre-
atinine ratio in dogs with mild and advanced stages of
CKD was similar in the present study. However, a lar-
ger number of dogs in the diﬀerent IRIS stages includ-
ing assessment of a muscle score might be useful in
assessing the inﬂuence of muscle mass on SDMA/crea-
tinine ratio in future prospective studies. Although
SDMA/creatinine ratio was signiﬁcantly diﬀerent in
dogs with AKI or CKD, a large overlap was present
Fig 2. Creatinine and symmetric dimethylarginine (SDMA) in healthy dogs and dogs with acute kidney injury (AKI) or chronic kidney
disease (CKD).
Fig 3. Symmetric dimethylarginine (SDMA) to creatinine ratio in
dogs with acute kidney injury (AKI) and chronic kidney disease
(CKD). Lines represent median and 25th–75th percentile.
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between the groups (Fig 3) and these results should not
be over-interpreted. Further studies, ideally including
GFR assessment, are necessary to elaborate the dispro-
portional elevation of SDMA as compared with crea-
tinine in dogs with AKI.
Most dogs included in the AKI group had advanced
kidney disease. Only three of the included dogs with
AKI could be classiﬁed with AKI grade II.a A conclu-
sion about SDMA in dogs with earlier grades of AKI
is therefore not possible. Further studies are needed
to analyze SDMA concentration in dogs with early
AKI, such as hospital acquired kidney disease. SDMA
might be of additional beneﬁt if early measurement is
possible.
A SDMA/creatinine ratio >10 has been reported to
carry a poor prognosis in dogs and cats with CKD.c
The prognostic value of SDMA/creatinine ratio is
thought to be a result of a disproportional increase of
SDMA compared to creatinine in animals with CKD.
The typical SDMA/creatinine ratio is <10 in the major-
ity of animals with CKD. The higher the ratio (>10),
the higher the risk of death in dogs and cats with
CKD.c However, SDMA/creatinine ratio was indepen-
dent of short-term survival for both dogs with AKI and
dogs with CKD in this study.
One dog with leptospirosis had a SDMA concentra-
tion well within the reference range (8 lg/dL) despite
having marked azotemia (creatinine concentration
4.2 mg/dL). A laboratory error was initially suspected,
but repeated measurements conﬁrmed the values.
Although this dog had hyperbilirubinemia in addition
to the severe azotemia, interference of biological sub-
stances with SDMA assay is highly unlikely, because of
lack of interference with hemoglobin, lipids, and biliru-
bin at the tested concentrations.16,26 Normalization of
GFR before normalization of creatinine would also be
possible, as creatinine usually lags behind. However,
this dog was anuric and blood work performed approxi-
mately 18 h later showed an increase of creatinine con-
centration from 4.2 mg/dL to 7.2 mg/dL, indicating
that the dog’s GFR was not recovering or normalizing.
Therefore the discrepancy in this dog remains unclear.
Storage time did not have an inﬂuence on the SDMA
concentration in a previous study.16 Whereas samples in
our study were stored for several years at 80°C, in this
individual dog inﬂuence of storage time is unlikely
because the storage time was comparable to that of the
other samples of the azotemic or healthy control dogs.
Two dogs with CKD also had a SDMA concentration
within the reference range. Both were classiﬁed as CKD
stage 1 with high normal creatinine concentration,
potentially explaining the normal SDMA concentration.
This study has several limitations. The ﬁrst limitation
is the lack of GFR measurements in the azotemic dogs.
Previous studies and also the healthy population in our
study show a good correlation between GFR, crea-
tinine, and SDMA concentration, but no information
about the relation of SDMA and GFR in dogs with
AKI is available.13,15,16,e A further limitation is that
SDMA/creatinine ratio could not be calculated in dogs
with SDMA values above the upper detection limit. As
this was only the case in four dogs, it is likely that this
has not confounded the analysis. All dogs with acute-
on-chronic kidney disease were excluded from further
analysis. However, because of the lack of clear identiﬁ-
cation criteria, some dogs might have been misclassiﬁed,
possibly aﬀecting the results. Follow-up to 30 days after
discharge was included in all reported dogs to ascertain
the disease status of the dogs, making misclassiﬁcation
less likely. Lastly the study lacks the determination of a
muscle score. This would have been helpful to evaluate
extrarenal inﬂuences on creatinine concentration.
In conclusion, plasma SDMA concentration is a suit-
able marker for identifying acute and chronic kidney
disease in dogs. Dogs with AKI have similar plasma
SDMA concentration as dogs with CKD and markedly
elevated SDMA concentration compared to healthy
dogs. In this population of dogs, the SDMA/creatinine
ratio was signiﬁcantly lower in the AKI group com-
pared with the CKD group for yet unknown reasons,
and further, prospective studies including a variety of
cases spanning across all IRIS AKI grades might help
to better understand the performance of this biomarker.
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